Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH⢠(tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Go back to Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH⢠(tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)| (NASDAQ: DNLI) | Delayed: 24.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.77 | 52 Week High | $ | |||
| Open | $24.77 | 52 Week Low | $ | |||
| Day High | $24.77 | P/E | N/A | |||
| Day Low | $24.77 | EPS | $ | |||
| Volume | 6,354 | |||||
